Webcast mRNA: A Game Changer for Vaccines

mRNA: A Game Changer for Vaccines

 · Australia/Victoria

About This Webcast

In the last 12 months mRNA has stepped into the spotlight as a successful strategy for vaccines, and while it may seem like a recent breakthrough, this exciting new era for vaccines is built on the backbone of decades of research. The use of mRNA as a therapeutic was first proposed by Dr Katalin Karikó in the early 1990s. Her research overcoming the challenges around introduced synthetic mRNA have been seminal in establishing its value for vaccine design. The mRNA-based COVID-19 vaccines have further served to accelerate acceptance and provide proof-of-concept that they are safe and effective, showing equal or greater protection against the virus when compared to traditional vaccines. As well as the use in vaccination against infectious diseases, mRNA boast significant potential as next generation therapies for the treatment of many other diseases including cancer. High quality In Vitro Transcription (IVT) of the synthetic mRNA is a major determinant for vaccine success, and choosing the correct IVT strategy involves how the mRNA is amplified, capped, tailed and purified. The reagents and processes used will not only ensure stable, functional mRNA is produced, but will also determine the scalability of mRNA synthesis as a vaccine candidate moves from the lab bench to gram-scale GMP manufacturing. New England Biolabs standalone reagents are readily available for IVT in formats matching our GMP-grade offering, enabling a seamless transition to large-scale therapeutic mRNA manufacturing. In this webinar, Dr Selva Ramasubramanian will discuss: History of mRNA as a therapeutic mRNA vaccines IVT mRNA workflow & strategies Upscaling and GMP manufacturing Tools and resources

Speakers

Selva Ramasubramanian, PhD

Selva Ramasubramanian, PhD

Field Application Scientist , New England Biolabs

Selva Ramasubramanian, PhD, is a Field Application Scientist at New England Biolabs, ANZ. She provides local support to our customers in Australia and New Zealand, specialising in RNA biology, CRISPR/Genome editing, and Next Generation Sequencing. Selva's career to-date includes a PhD at the Max Planck Institute in Germany, Biopharmaceutical experience in Monoclonal Antibody Characterization, and Management of the Single Cell Genomics Core Facility at Monash Health.